ARS Pharmaceuticals, Inc. (SPRY) Cash and Cash Equivalents

Annual Cash & Cash Equivalents:

$314.02M+$85.66M(+37.51%)
December 31, 2024

Summary

  • As of today, SPRY annual cash & cash equivalents is $314.02 million, with the most recent change of +$85.66 million (+37.51%) on December 31, 2024.
  • During the last 3 years, SPRY annual cash & cash equivalents has risen by +$253.96 million (+422.82%).
  • SPRY annual cash & cash equivalents is now -18.77% below its all-time high of $386.57 million, reached on December 1, 2020.

Performance

SPRY Cash and Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSPRYbalance sheet metrics

Quarterly Cash & Cash Equivalents:

$288.21M+$48.08M(+20.02%)
September 30, 2025

Summary

  • As of today, SPRY quarterly cash & cash equivalents is $288.21 million, with the most recent change of +$48.08 million (+20.02%) on September 30, 2025.
  • Over the past year, SPRY quarterly cash & cash equivalents has increased by +$83.58 million (+40.85%).
  • SPRY quarterly cash & cash equivalents is now -25.44% below its all-time high of $386.57 million, reached on December 1, 2020.

Performance

SPRY Quarterly Cash & Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSPRYbalance sheet metrics

Cash and Cash Equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

SPRY Cash and Cash Equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1Y1 Year+37.5%+40.9%
3Y3 Years+422.8%+8.1%
5Y5 Years+3047.8%-25.4%

SPRY Cash and Cash Equivalents Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs Low
3Y3-Yearat high+422.8%-8.2%+40.9%
5Y5-Year-18.8%+422.8%-25.4%+40.9%
All-TimeAll-Time-18.8%+3047.8%-25.4%+2789.0%

SPRY Cash and Cash Equivalents History

DateAnnualQuarterly
Sep 2025
-
$288.21M(+20.0%)
Jun 2025
-
$240.13M(-12.9%)
Mar 2025
-
$275.73M(-12.2%)
Dec 2024
$314.02M(+37.5%)
$314.02M(+53.5%)
Sep 2024
-
$204.62M(-6.5%)
Jun 2024
-
$218.74M(-2.2%)
Mar 2024
-
$223.63M(-2.1%)
Dec 2023
$228.36M(-16.8%)
$228.36M(-5.6%)
Sep 2023
-
$241.90M(-4.1%)
Jun 2023
-
$252.21M(-4.7%)
Mar 2023
-
$264.55M
DateAnnualQuarterly
Dec 2022
$274.38M(+356.8%)
-
Sep 2022
-
$266.62M(+3.4%)
Jun 2022
-
$257.98M(+1.6%)
Mar 2022
-
$253.85M(-0.1%)
Dec 2021
$60.06M(-84.5%)
-
Dec 2021
-
$254.04M(-15.5%)
Sep 2021
-
$300.66M(-16.4%)
Jun 2021
-
$359.69M(-3.9%)
Mar 2021
-
$374.20M(-3.2%)
Dec 2020
$386.57M(+3775.0%)
$386.57M(+3775.0%)
Dec 2019
$9.98M(-50.5%)
$9.98M
Dec 2018
$20.16M
-

FAQ

  • What is ARS Pharmaceuticals, Inc. annual cash & cash equivalents?
  • What is the all-time high annual cash & cash equivalents for ARS Pharmaceuticals, Inc.?
  • What is ARS Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
  • What is ARS Pharmaceuticals, Inc. quarterly cash & cash equivalents?
  • What is the all-time high quarterly cash & cash equivalents for ARS Pharmaceuticals, Inc.?
  • What is ARS Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?

What is ARS Pharmaceuticals, Inc. annual cash & cash equivalents?

The current annual cash & cash equivalents of SPRY is $314.02M

What is the all-time high annual cash & cash equivalents for ARS Pharmaceuticals, Inc.?

ARS Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $386.57M

What is ARS Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?

Over the past year, SPRY annual cash & cash equivalents has changed by +$85.66M (+37.51%)

What is ARS Pharmaceuticals, Inc. quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of SPRY is $288.21M

What is the all-time high quarterly cash & cash equivalents for ARS Pharmaceuticals, Inc.?

ARS Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $386.57M

What is ARS Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?

Over the past year, SPRY quarterly cash & cash equivalents has changed by +$83.58M (+40.85%)
On this page